H. Lundbeck A/S/€HLUNB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.
Ticker
€HLUNB
Sector
Primary listing
XGAT
Employees
5,700
Headquarters
Valby, Denmark
Website
H. Lundbeck A/S Metrics
BasicAdvanced
€5.7B
13.13
€0.47
0.38
€0.13
2.06%
Price and volume
Market cap
€5.7B
Beta
0.38
52-week high
€6.43
52-week low
€3.64
Average daily volume
22K
Dividend rate
€0.13
Financial strength
Current ratio
1.595
Quick ratio
1.078
Long term debt to equity
56.085
Total debt to equity
56.42
Dividend payout ratio (TTM)
27.06%
Interest coverage (TTM)
8.06%
Profitability
EBITDA (TTM)
951.698
Gross margin (TTM)
81.55%
Net profit margin (TTM)
14.82%
Operating margin (TTM)
22.85%
Effective tax rate (TTM)
15.56%
Revenue per employee (TTM)
€553,040
Management effectiveness
Return on assets (TTM)
7.39%
Return on equity (TTM)
14.70%
Valuation
Price to earnings (TTM)
13.131
Price to revenue (TTM)
1.946
Price to book
1.78
Price to tangible book (TTM)
-3.7
Price to free cash flow (TTM)
16.051
Free cash flow yield (TTM)
6.23%
Free cash flow per share (TTM)
0.385
Dividend yield (TTM)
2.06%
Forward dividend yield
2.06%
Growth
Revenue change (TTM)
13.79%
Earnings per share change (TTM)
34.80%
3-year revenue growth (CAGR)
11.62%
10-year revenue growth (CAGR)
5.61%
3-year earnings per share growth (CAGR)
41.53%
10-year earnings per share growth (CAGR)
-2.86%
3-year dividend per share growth (CAGR)
33.42%
Bulls say / Bears say
In August 2025, Lundbeck raised its full-year 2025 revenue growth guidance to 11–13% and adjusted EBITDA growth guidance to 16–21%, up from 8–11% and 8–14% respectively, reflecting stronger-than-expected mid-year performance (Reuters).
Lundbeck’s strategic brands grew by 24% at constant exchange rates in Q1 2025, led by Vyepti’s 62% growth and Rexulti’s 28% increase, indicating robust demand across its core CNS portfolio (Lundbeck).
The company secured a €500 million senior unsecured bond issuance in May 2025 at a leverage-neutral 3.375% coupon, maintaining its BBB− credit rating and reinforcing financial flexibility for R&D investments (Reuters).
A U.S. FDA advisory panel voted 10–1 against the brexpiprazole-sertraline regimen for PTSD in July 2025, citing insufficient efficacy data, which could delay or derail this indication’s approval and future revenue potential (Reuters).
On September 20, 2025, the FDA issued a Complete Response Letter for Lundbeck’s supplemental NDA of REXULTI in PTSD, stating that additional adequate trials are needed to demonstrate effectiveness, marking a significant regulatory setback (Otsuka).
Shares of H. Lundbeck fell around 5.5% after the company reported a Q4 revenue miss in February 2025, with key drugs Rexulti and Vyepti underperforming consensus expectations, highlighting market sensitivity to product sales variance (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for H. Lundbeck A/S stock?
H. Lundbeck A/S (HLUNB) has a market cap of €5.7B as of November 10, 2025.
What is the P/E ratio for H. Lundbeck A/S stock?
The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUNB) stock is 13.13 as of November 10, 2025.
Does H. Lundbeck A/S stock pay dividends?
Yes, the H. Lundbeck A/S (HLUNB) stock pays dividends to shareholders. As of November 10, 2025, the dividend rate is €0.12727 and the yield is 2.06%. H. Lundbeck A/S has a payout ratio of 27.06% on a trailing twelve-month basis.
When is the next H. Lundbeck A/S dividend payment date?
The next H. Lundbeck A/S (HLUNB) dividend payment date is unconfirmed.
What is the beta indicator for H. Lundbeck A/S?
H. Lundbeck A/S (HLUNB) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.